These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 22759751

  • 1. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.
    Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD, Groopman J, Chemin I, Hainaut P.
    Carcinogenesis; 2012 Jun; 33(6):1219-24. PubMed ID: 22759751
    [Abstract] [Full Text] [Related]

  • 2. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.
    Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van der Sande M, Whittle H, Friesen MD, Groopman JD, Hainaut P.
    Environ Health Perspect; 2011 Nov; 119(11):1635-40. PubMed ID: 21768053
    [Abstract] [Full Text] [Related]

  • 3. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand.
    Ortiz-Cuaran S, Villar S, Gouas D, Ferro G, Plymoth A, Khuhaprema T, Kalalak A, Sangrajrang S, Friesen MD, Groopman JD, Hainaut P.
    Cancer Lett; 2013 Apr 30; 331(1):46-51. PubMed ID: 23200676
    [Abstract] [Full Text] [Related]

  • 4. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.
    Marchio A, Amougou Atsama M, Béré A, Komas NP, Noah Noah D, Atangana PJA, Camengo-Police SM, Njouom R, Bekondi C, Pineau P.
    Clin Exp Med; 2018 Aug 30; 18(3):421-431. PubMed ID: 29749584
    [Abstract] [Full Text] [Related]

  • 5. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
    Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL.
    Carcinogenesis; 2010 Aug 30; 31(8):1475-82. PubMed ID: 20538734
    [Abstract] [Full Text] [Related]

  • 6. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
    Szymañska K, Chen JG, Cui Y, Gong YY, Turner PC, Villar S, Wild CP, Parkin DM, Hainaut P.
    Cancer Epidemiol Biomarkers Prev; 2009 May 30; 18(5):1638-43. PubMed ID: 19366907
    [Abstract] [Full Text] [Related]

  • 7. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X, Zhang Q, Li B, Du Y, Yin J, Liu W, Zhang H, Cao G.
    Infect Genet Evol; 2014 Dec 30; 28():201-9. PubMed ID: 25281206
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg).
    Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y.
    Asian Pac J Cancer Prev; 2013 Dec 30; 14(12):7675-9. PubMed ID: 24460352
    [Abstract] [Full Text] [Related]

  • 9. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.
    Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, Gouas D, Nogueira da Costa A, Plymoth A, Khuhaprema T, Kalalak A, Sangrajrang S, Friesen MD, Groopman JD, Hainaut P.
    PLoS One; 2012 Dec 30; 7(6):e37707. PubMed ID: 22675488
    [Abstract] [Full Text] [Related]

  • 10. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
    Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J.
    Gut; 2015 May 30; 64(5):820-9. PubMed ID: 25021421
    [Abstract] [Full Text] [Related]

  • 11. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
    Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, Peng T, Han ZG, Li LQ.
    Liver Int; 2015 Mar 30; 35(3):999-1009. PubMed ID: 24461059
    [Abstract] [Full Text] [Related]

  • 12. Hepatocellular carcinoma and the underlying mechanisms.
    Oyagbemi AA, Azeez OI, Saba AB.
    Afr Health Sci; 2010 Mar 30; 10(1):93-8. PubMed ID: 20811532
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand.
    Thongbai C, Sa-nguanmoo P, Kranokpiruk P, Poovorawan K, Poovorawan Y, Tangkijvanich P.
    Asian Pac J Cancer Prev; 2013 Mar 30; 14(6):3555-9. PubMed ID: 23886144
    [Abstract] [Full Text] [Related]

  • 14. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53.
    Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, Tsutsumi A, Noguchi N, Takano Y, Yashima K, Kishimoto Y, Suou T, Kawasaki H.
    J Med Virol; 2000 Oct 30; 62(2):151-8. PubMed ID: 11002243
    [Abstract] [Full Text] [Related]

  • 15. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma.
    Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA, Gao HJ, Zhu MH.
    World J Gastroenterol; 2008 Mar 07; 14(9):1346-52. PubMed ID: 18322946
    [Abstract] [Full Text] [Related]

  • 16. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.
    Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V.
    Clin Microbiol Infect; 2019 Jul 07; 25(7):906.e1-906.e7. PubMed ID: 30472417
    [Abstract] [Full Text] [Related]

  • 17. A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines.
    Shi Y, Wang J, Wang Y, Wang A, Guo H, Wei F, Mehta SR, Espitia S, Smith DM, Liu L, Zhang Y, Chen D.
    Cancer Lett; 2016 Feb 28; 371(2):285-91. PubMed ID: 26706415
    [Abstract] [Full Text] [Related]

  • 18. Polymorphism analyses of hepatitis B virus X gene in hepatocellular carcinoma patients from southern China.
    Zhu P, Tan D, Peng Z, Liu F, Song L.
    Acta Biochim Biophys Sin (Shanghai); 2007 Apr 28; 39(4):265-72. PubMed ID: 17417681
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China.
    Li W, Chen G, Yu X, Shi Y, Peng M, Wei J.
    Int J Clin Exp Pathol; 2013 Apr 28; 6(6):1076-85. PubMed ID: 23696925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.